St Hill Medical
Innovative Healthcare Solutions
St Hill Medical is a medical device company with dedication towards providing cutting-edge solutions in the fields of anaesthesia, critical care, emergency medicine and cardiorespiratory illnesses. Our team comprises of expert physicians, surgeons and researchers having profound knowledge in the said domains.
Our focus is on developing new generation airway devices and innovative technologies to treat a wide range of cardiorespiratory conditions, including cardiac and respiratory failure.
OUR DEVICES AND TECHNOLOGIES
(click on the images below to know more)
IMPLANTABLE OXYGENATOR DEVICE TO TREAT RESPIRATORY FAILURE
RESPIRATORY FAILURE
AVAILBALE TREATMENT OPTIONS
AVAILBALE TREATMENT OPTIONS
Average adult uses 250 cc of dissolved Oxygen gas per minute for his/her metabolic requirement. The inability of the lungs to meet this oxygen demand, or eliminate the carbon dioxide generated thereof, is termed “Respiratory failure”, which can be either acute/reversible or chronic/irreversible. COVID-19 is one of the conditions which can cause acute respiratory failure in pandemic proportions.
AVAILBALE TREATMENT OPTIONS
AVAILBALE TREATMENT OPTIONS
AVAILBALE TREATMENT OPTIONS
The available treatment options for acute respiratory failure are mechanical ventilation through a tracheal tube, tracheostomy, or Extracorporeal oxygenation (ECMO). Chronic respiratory failure generally needs lung transplantation.
IMPLANTABLE OXYGENATOR
AVAILBALE TREATMENT OPTIONS
IMPLANTABLE OXYGENATOR
By developing an implantable oxygenator, we can maintain oxygenation without the need for tracheal intubation, tracheostomy, ECMO or lung transplant in patients suffering from respiratory failure.
We have successfully developed and validated in-vitro models and are currently in the process of translational research.
CLEVERPUMP WITH REGENHEART TECHNOLOGY:TREATING HEART FAILURE
HEART FAILURE
CLEVERPUMP WITH REGENHEART TECHNOLOGY
AVAILABLE TREATMENT OPTIONS
Average adult humans need about 5.5 liters of blood to be pumped around the body per minute. Inability of the heart to pump enough blood to meet the metabolic demands of the body is known as heart failure. This condition affects over 64 million people worldwide. Global economic burden due to heart failure was USD 346.17 Billion in 2020.
AVAILABLE TREATMENT OPTIONS
CLEVERPUMP WITH REGENHEART TECHNOLOGY
AVAILABLE TREATMENT OPTIONS
The treatment options available for end stage heart failure are heart transplantation and LVAD therapy.
Heart transplantation is limited by donor organ availability.
LVAD therapy is limited by high cost and high rate of long-term complications (Stroke, gastrointestinal bleeding, driveline sepsis etc,.)
CLEVERPUMP WITH REGENHEART TECHNOLOGY
CLEVERPUMP WITH REGENHEART TECHNOLOGY
CLEVERPUMP WITH REGENHEART TECHNOLOGY
Even in the end stage heart failure, most cardiac muscle is not structurally dead, they are only hibernating (non-functioning).
Our invention, the CleverPump, is designed to re-awaken the hibernating cardiac muscle along with regenerating the dead myocardial segments. This two-pronged approach results in "Bridge to accelerated recovery" of
Even in the end stage heart failure, most cardiac muscle is not structurally dead, they are only hibernating (non-functioning).
Our invention, the CleverPump, is designed to re-awaken the hibernating cardiac muscle along with regenerating the dead myocardial segments. This two-pronged approach results in "Bridge to accelerated recovery" of the heart muscle, after which the device can be explanted (after about 12 months of implantation)
BREEZAMASK: NOVEL THIRD GEN LARYNGEAL MASK WITH DYNAMIC CUFF
BREEZAMASK
MANNEQUIN & PILOT STUDIES
BREEZAMASK
´BreezamaskTM is an innovative third generation Supraglottic airway device with a self-inflating cuff system which gets inflated only during the inspiratory phase of positive pressure ventilation and gets deflated during the expiratory phase, thereby minimising the risk of nerve injuries and simultaneously improving airway seal pressures (30-40 cm of H2O)
BREEZAMASK
MANNEQUIN & PILOT STUDIES
BREEZAMASK
Breezamask is made of medical grade silicone and is latex-free. It is currently available in 2 adult sizes: size #3 (for height between 4'10 till 5'6") and size #4 (for height between 5'7" and 6'4")
´The self-inflating cuff system has two self inflating cuffs of which one expands in anteroposterior direction and the other expands in late
Breezamask is made of medical grade silicone and is latex-free. It is currently available in 2 adult sizes: size #3 (for height between 4'10 till 5'6") and size #4 (for height between 5'7" and 6'4")
´The self-inflating cuff system has two self inflating cuffs of which one expands in anteroposterior direction and the other expands in lateral direction, ensuring an all-round seal.
There is also a oesophageal drainage port which can accommodate large bore gastric tubes (16Fr in #3, 18Fr in #4)
MANNEQUIN & PILOT STUDIES
MANNEQUIN & PILOT STUDIES
MANNEQUIN & PILOT STUDIES
In mannequin and pilot studies, Breezamask was able to maintain an oropharyngeal airway seal of 30-40 cm of H2O, which is superior to other available supraglottic airway devices. The ease of insertion, first attempt success-rate, time taken for insertion etc., were also superior to other supraglottic airway devices.
OXYDUCT-3G: NOVEL THIRD GENERATION VENTILATION BOUGIE
OXYDUCT-3G
CADAVERIC TRIALS: RETROGRADE INTUBATION/FONA
MANNEQUINN TRIALS
“OxyDuct-3G”, has a 13 Fr hollow body, a standard 15 mm connector in its proximal end and an elastic, self-inflating “dynamic” cuff near its distal end. This “dynamic” silicone cuff gets inflated during positive pressure ventilation, and seals the tracheal lumen from inside. This “dynamic sealing” of the trachea, ensures excellent ventilation.
OxyDuct-3G also has a colour coding system(dual-colour zone in 25-40cm mark; black-zone beyond 40cm mark). While attempting intubation, if black-zone is seen at the lip level, it indicates that the distal tip lies in the oesophagus. This will prevent oesophageal intubation. The dual-colour zone will allow selective one-lung ventilation and selective bronchial intubation.
MANNEQUINN TRIALS
CADAVERIC TRIALS: RETROGRADE INTUBATION/FONA
MANNEQUINN TRIALS
In mannequin trials, OxyDuct-3G was able to deliver consistently 300 mL tidal volume with a self-inflating resuscitator bag ("Ambu"Bag/ Laerdal resuscitator). In comparison, Frova Intubating Introducer was able to deliver only 30-40 mL tidal volume per breath (Click on the picture to see the full video)
CADAVERIC TRIALS: RETROGRADE INTUBATION/FONA
CADAVERIC TRIALS: RETROGRADE INTUBATION/FONA
CADAVERIC TRIALS: RETROGRADE INTUBATION/FONA
OxyDuct-3G performed extremely well in cadaveric trials for tracheal intubation, retrograde intubation and Cricothyrotomy (Front Of the Neck Airway: FONA). (Click on the picture to see the full video)
CRICODILE: EMERGENCY FRONT OF NECK AIRWAY DEVICE
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
“Can’t intubate – Can’t oxygenate” (CICO) situation is a nightmare for any anaesthesiologist. In such situations, most patients tend to desaturate. In such situations, Difficult Airway Society (DAS) recommends the ‘Scalpel-Bougie-Tube’ technique, for emergency cricothyrotomy. Here, a scalpel is used to create an 8-9 mm incision in the n
“Can’t intubate – Can’t oxygenate” (CICO) situation is a nightmare for any anaesthesiologist. In such situations, most patients tend to desaturate. In such situations, Difficult Airway Society (DAS) recommends the ‘Scalpel-Bougie-Tube’ technique, for emergency cricothyrotomy. Here, a scalpel is used to create an 8-9 mm incision in the neck, through which a bougie is introduced into the trachea and a 6.0mm cuffed tracheal tube (outer diameter about 8.8mm) is railroaded over the bougie into the trachea. This is done as the available ventilating bougies don’t have stand-alone ventilation capabilities (delivery of 200-300 cc of tidal volume consistently) sufficient to overcome the anatomical dead space (150 cc). Insertion of a 6.0 mm tracheal tube into the trachea through the cricothyroid membrane in a desaturating patient can be quite unnerving even for the most experienced anaesthesiologists/ intensivists. In these situations, our novel cricothyrotomy device “CricoDile” can be of immense help.
CRICODILE
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
Our invention, “CricoDile”, has a 13 Fr hollow body of length 25 cm and outer diameter of 4.3 mm, a standard 15 mm connector in its proximal end and an elastic, self-inflating “dynamic” cuff made of medical grade silicone near its distal end. This “dynamic” silicone cuff gets inflated during positive pressure ventilation, and seals the t
Our invention, “CricoDile”, has a 13 Fr hollow body of length 25 cm and outer diameter of 4.3 mm, a standard 15 mm connector in its proximal end and an elastic, self-inflating “dynamic” cuff made of medical grade silicone near its distal end. This “dynamic” silicone cuff gets inflated during positive pressure ventilation, and seals the tracheal lumen from inside. This “dynamic sealing” design ensures CricoDile's 'stand-alone' ventilation capability.
CricoDile can be inserted into the trachea either using a direct insertion technique (using a scalpel) or through a percutaneous (Seldinger's railroading) technique.
In rare situations, where there is a need for prolonged ventilation support, a 6.5 no. tracheostomy tube can be railroaded over CricoDile into the trachea
MANNEQUIN STUDY FOR FRONT OF NECK AIRWAY (FONA)
EMERGENCY FRONT OF NECK AIRWAY (FONA)/CRICOTHYROTOMY
MANNEQUIN STUDY FOR FRONT OF NECK AIRWAY (FONA)
In mannequin trials, through cricothyrotomy (FONA), CricoDile was able to deliver consistently 500-600 mL tidal volume with a self-inflating resuscitator bag ("Ambu"Bag/ Laerdal resuscitator). In comparison, Frova Intubating Introducer was able to deliver only less than 100 mL tidal volume per breath (Click on the picture to see the full video)
THE TEAM
DR KALYAN ANANTHANARAYANAN, FOUNDER & CEO
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
DR KALYAN ANANTHANARAYANAN, FOUNDER & CEO
Dr Kalyan is a physician with more than 2 decades of experience in Cardiothoracic anaesthesia and Cardiorespiratory intensive care. He specializes in mechanical circulatory support for cardiorespiratory failure including ECMO, heart and lung transplants.
DR DHEERAJ REDDY, DIRECTOR
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
DR KALYAN ANANTHANARAYANAN, FOUNDER & CEO
Dr Dheeraj Reddy is a cardiac surgeon with more than 15 years experience in the domain. He specialises in coronary revasularisation and surgical treatment for heart failure.
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
Dr Srinivasan is a Translational research scientist with 10+ years’ experience in regenerative medicine and biomedical applications in academic and corporate environments. Principal/co-investigator who initiates and translates novel areas of research from bench to bedside. Has mentored 50+ scientists/students
PROF. DEEPAK TEMPE, SCIENTIFIC ADVISOR
PROF. DEEPAK TEMPE, SCIENTIFIC ADVISOR
DR ABIRAMAN SRINIVASAN, CHIEF SCIENTIFIC ADVISOR
Prof Tempe is a doyen of cardiothoracic anaesthesia and cardiorespiratory intensive care in India, with more than 4 decades of experience in the domains. He was formerly the Director and Dean of Maulana Azad Medical College, New Delhi. He is presently the Officiating Vice Chancellor of Institute of Hepatobiliary Sciences (ILBS), New Delhi.
DR GOKULAKRISHNAN.M, DIRECTOR
PROF. DEEPAK TEMPE, SCIENTIFIC ADVISOR
MS DEEPA VENKATRAMAN, DIRECTOR
Dr Gokulakrishnan is a physician having more than 2 decades experience in cardiothoracic anaesthesia and cardiorespiratory intensive care. He specializes in heart and lung transplants and mechanical circulatory support (ECMO)
MS DEEPA VENKATRAMAN, DIRECTOR
PROF. DEEPAK TEMPE, SCIENTIFIC ADVISOR
MS DEEPA VENKATRAMAN, DIRECTOR
Ms. Venkatraman specializes in material science, product development and validation.
AWARDS AND HONOURS
APOLLO INNOVATION AWARDS 2023
BEST INNOVATION AWARD AT ISACON 2023
BEST INNOVATION AWARD AT ISACON 2023
Our invention OXYDUCT-3G won the award for the best innovation in nation-wide Apollo Awards for Excellence under the category Clinical Innovations for the year 2023.
BEST INNOVATION AWARD AT ISACON 2023
BEST INNOVATION AWARD AT ISACON 2023
BEST INNOVATION AWARD AT ISACON 2023
Our invention OXYDUCT-3G won the award for the best innovation in ISACON 2023, the national conference of the Indian Society of Anaesthesiologists.